Involvement in the planning and conduct of the study (applies to both AstraZeneca staff and staff at third party vendor or at the investigational sites).
Previous enrolment in the present study or participation in another clinical study with an investigational product during the last 3 months or as judged by the Investigator.
History of or presence of any clinically significant disease or disorder including a recent (< 3 months) cardiovascular event which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study or influence the results or the patient's ability to participate in the study.
Clinical diagnosis of Type 1 diabetes, maturity onset diabetes of the young, secondary diabetes or diabetes insipidus.
Unstable/rapidly progressing renal disease or estimated Glomerular Filtration Rate < 60 mL/min (Cockcroft-Gault formula).
Clinically significant out of range values of serum levels of either alanine aminotransferase (ALT), aspartate aminotransferase (AST) or alkaline phosphatase (ALP) in the Investigator's opinion.
Contraindications to dapagliflozin according to the local label.
Use of antidiabetic drugs other than metformin within 3 months prior to screening.
Weight gain or loss > 5 kg in the last 3 months, ongoing weight-loss diet (hypocaloric diet) or use of weight loss agents.
History of drug abuse or alcohol abuse in the past 12 months.
Any clinically significant abnormalities in clinical chemistry, hematology or urinalysis or other condition the Investigator believes would interfere with the patient's ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the patient at undue risk.
Plasma donation within one month of screening or any blood donation/blood loss > 500 mL within 3 months prior to screening or during the study.
Anemia defined as Hemoglobin (Hb) < 115 g/L (7.1 mM) in women and < 120 g/L (7.5 mM) in men.
Use of anti-coagulant treatment such as heparin, warfarin, platelet inhibitors, thrombin and factor X inhibitors.
Use of medication such as oral glucocorticoids, anti-estrogens or other medications that are known to markedly influence insulin sensitivity.
Use of loop diuretics.
Regular smoking and other regular nicotine use.
Central nervous system aneurysm clip
Implanted neural stimulator
Implanted cardiac pacemaker of defibrillator
Cochlear implant
Metal containing corpora aliena in the eye or brain.
Patients, who do not want to be informed about unexpected medical findings, or do not wish that their physician be informed about coincidental findings, cannot participate in the study.

NCT03338855_exc_T3
Qualifier
clinically significant
NCT03338855_exc_T4
Condition
disease
NCT03338855_exc_T5
Condition
disorder
NCT03338855_exc_T6
Temporal
recent
NCT03338855_exc_T7
Temporal
< 3 months
NCT03338855_exc_T8
Condition
cardiovascular event
NCT03338855_exc_T10
Condition
Type 1 diabetes
NCT03338855_exc_T11
Condition
maturity onset diabetes of the young
NCT03338855_exc_T12
Condition
secondary diabetes
NCT03338855_exc_T13
Condition
diabetes insipidus
NCT03338855_exc_T14
Qualifier
rapidly progressing
NCT03338855_exc_T15
Qualifier
Unstable
NCT03338855_exc_T16
Condition
renal disease
NCT03338855_exc_T17
Measurement
estimated Glomerular Filtration Rate
NCT03338855_exc_T18
Value
< 60 mL/min
NCT03338855_exc_T19
Qualifier
Cockcroft-Gault formula
NCT03338855_exc_T20
Scope
Unstable/rapidly progressing
NCT03338855_exc_T21
Qualifier
Clinically significant
NCT03338855_exc_T22
Value
out of range values
NCT03338855_exc_T23
Measurement
alanine aminotransferase (ALT)
NCT03338855_exc_T24
Measurement
aspartate aminotransferase (AST)
NCT03338855_exc_T25
Measurement
alkaline phosphatase (ALP)
NCT03338855_exc_T26
Scope
alanine aminotransferase (ALT), aspartate aminotransferase (AST) or alkaline phosphatase (ALP)
NCT03338855_exc_T27
Drug
dapagliflozin
NCT03338855_exc_T28
Condition
Contraindications
NCT03338855_exc_T29
Drug
antidiabetic drugs
NCT03338855_exc_T30
Drug
metformin
NCT03338855_exc_T31
Negation
other than
NCT03338855_exc_T32
Temporal
within 3 months prior to screening
NCT03338855_exc_T33
Measurement
Weight gain
NCT03338855_exc_T34
Measurement
ain or  k
NCT03338855_exc_T35
Value
> 5 kg
NCT03338855_exc_T36
Temporal
in the last 3 months
NCT03338855_exc_T37
Observation
weight-loss diet
NCT03338855_exc_T38
Temporal
ongoing
NCT03338855_exc_T39
Observation
hypocaloric diet
NCT03338855_exc_T40
Drug
weight loss agents
NCT03338855_exc_T41
Scope
Weight gain or loss
NCT03338855_exc_T42
Observation
alcohol abuse
NCT03338855_exc_T43
Observation
drug abuse
NCT03338855_exc_T44
Temporal
in the past 12 months
NCT03338855_exc_T45
Scope
drug abuse or alcohol abuse
NCT03338855_exc_T46
Observation
History
NCT03338855_exc_T48
Procedure
Plasma donation
NCT03338855_exc_T49
Temporal
within one month of screening
NCT03338855_exc_T50
Reference_point
screening
NCT03338855_exc_T51
Procedure
blood donation
NCT03338855_exc_T52
Measurement
blood loss
NCT03338855_exc_T53
Value
> 500 mL
NCT03338855_exc_T54
Scope
blood donation/blood loss > 500 mL
NCT03338855_exc_T55
Temporal
within 3 months prior to screening
NCT03338855_exc_T56
Temporal
during the study
NCT03338855_exc_T57
Scope
within 3 months prior to screening or during the study
NCT03338855_exc_T58
Condition
Anemia
NCT03338855_exc_T59
Measurement
Hemoglobin (Hb)
NCT03338855_exc_T60
Value
< 115 g/L
NCT03338855_exc_T61
Value
7.1 mM
NCT03338855_exc_T62
Person
women
NCT03338855_exc_T63
Value
< 120 g/L
NCT03338855_exc_T64
Value
7.5 mM
NCT03338855_exc_T65
Person
men
NCT03338855_exc_T66
Scope
< 115 g/L (7.1 mM) in women and < 120 g/L (7.5 mM) in men
NCT03338855_exc_T67
Scope
Hemoglobin (Hb) < 115 g/L (7.1 mM) in women and < 120 g/L (7.5 mM) in men
NCT03338855_exc_T68
Procedure
anti-coagulant treatment
NCT03338855_exc_T69
Drug
heparin
NCT03338855_exc_T70
Drug
warfarin
NCT03338855_exc_T71
Drug
platelet inhibitors
NCT03338855_exc_T72
Drug
thrombin
NCT03338855_exc_T73
Drug
factor X inhibitors
NCT03338855_exc_T74
Scope
heparin, warfarin, platelet inhibitors, thrombin and factor X inhibitor
NCT03338855_exc_T75
Drug
oral glucocorticoids
NCT03338855_exc_T76
Drug
anti-estrogens
NCT03338855_exc_T77
Drug
medications
NCT03338855_exc_T78
Qualifier
other
NCT03338855_exc_T79
Qualifier
markedly influence insulin sensitivity
NCT03338855_exc_T80
Scope
oral glucocorticoids, anti-estrogens or other medications
NCT03338855_exc_T81
Drug
loop diuretics
NCT03338855_exc_T82
Observation
smoking
NCT03338855_exc_T83
Multiplier
Regular
NCT03338855_exc_T84
Drug
nicotine
NCT03338855_exc_T85
Multiplier
regular
NCT03338855_exc_T86
Device
Central nervous system aneurysm clip
NCT03338855_exc_T87
Device
Implanted neural stimulator
NCT03338855_exc_T88
Device
cardiac pacemaker
NCT03338855_exc_T89
Device
defibrillator
NCT03338855_exc_T90
Device
Cochlear implant
NCT03338855_exc_T91
Device
corpora aliena in the eye
NCT03338855_exc_T92
Device
 eye or brain.
Patie do no
NCT03338855_exc_T93
Qualifier
Metal containing